The research indicates that the new targetable cells have the potential to reduce relapse in patients with solid tumors.
For more than 20 years, Sigmund Hultqvist, Stockholm University bioengineer, has worked with his colleague Karl theodorou to develop new cancer-targeting immunotherapies.
Among the most successful obstacles have been the observed effect in cancer cells.
The research, conducted with colleagues in Finland and Japan and funded by Sigmund’s lab in Stockholm, Sweden, has just been published in Trends in Immunology (TIM) and will be extended into high-throughput screening and clinical trials. Continue reading →